Daniel Gerlach

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 10

Top Venues

Nature cancer

Cancer discovery

Oncogene

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Venu Thatikonda, Hengyu Lu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Christoph Albrecht, Donát Alpár, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A Machado, Thomas Madensky, Ethan D Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M Molkentine, Philipp A Jaeger, David H Peng, Robyn L Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Edmund S Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene C Waizenegger, Marco H Hofmann
Co-targeting SOS1 enhances the antitumor effects of KRAS G12C inhibitors by addressing intrinsic and acquired resistance. Nature cancer (2024)
Venu Thatikonda, Hengyu Lu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Christoph Albrecht, Donát Alpár, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A Machado, Thomas Madensky, Ethan D Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M Molkentine, Philipp A Jaeger, David H Peng, Robyn L Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Edmund S Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene C Waizenegger, Marco H Hofmann
Co-targeting SOS1 enhances the antitumor effects of KRAS G12C inhibitors by addressing intrinsic and acquired resistance. Nature cancer (2024)
Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Juergen Ramharter, Rolf Grempler, Jens Quant, Joerg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl, Guido Boehmelt, Darryl B McConnell, Norbert Kraut, Patrizia Sini
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules. Molecular cancer therapeutics (2024)
Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson, Irene C Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer, Yukina Shirai, Masachika Ikegami, Sylvia Tilandyova, Dirk Scharn, Mark A Pearson, Johannes Popow, Anna C Obenauf, Noboru Yamamoto, Shunsuke Kondo, Frans L Opdam, Annemarie Bruining, Shinji Kohsaka, Norbert Kraut, John Victor Heymach, Flavio Solca, Ralph A Neumuller
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. Cancer discovery (2024)
Birgit Wilding, Dirk Scharn, Dietrich Böse, Anke Baum, Valeria Santoro, Paolo Chetta, Renate Schnitzer, Dana A Botesteanu, Christoph Reiser, Stefan Kornigg, Petr Knesl, Alexandra Hörmann, Anna Köferle, Maja Corcokovic, Simone Lieb, Guido Scholz, Jens Bruchhaus, Markus Spina, Josef Balla, Biljana Peric-Simov, Jasmin Zimmer, Sophie Mitzner, Thomas N Fett, Alexandra Beran, Lyne Lamarre, Thomas Gerstberger, Daniel Gerlach, Markus Bauer, Andreas Bergner, Andreas Schlattl, Gerd Bader, Matthias Treu, Harald Engelhardt, Stephan Zahn, Julian E Fuchs, Johannes Zuber, Peter Ettmayer, Mark Pearson, Mark Petronczki, Norbert Kraut, Darryl B McConnell, Flavio Solca, Ralph A Neumuller
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nature cancer 3 (7) (2022)
Marco H Hofmann, Daniel Gerlach, Sandra Misale, Mark Petronczki, Norbert Kraut
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer discovery 12 (4) (2022)
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, Fabio Savarese, Daniel Gerlach, Joseph R Marszalek, Michael P Sanderson, Dirk Kessler, Francesca Trapani, Heribert Arnhof, Klaus Rumpel, Dana-Adriana Botesteanu, Peter Ettmayer, Thomas Gerstberger, Christiane Kofink, Tobias Wunberg, Andreas Zoephel, Szu-Chin Fu, Jessica L F Teh, Jark Böttcher, Nikolai Pototschnig, Franziska Schachinger, Katharina Schipany, Simone Lieb, Christopher P Vellano, Jonathan C O'Connell, Rachel L Mendes, Jurgen Moll, Mark Petronczki, Timothy P Heffernan, Mark Pearson, Darryl B McConnell, Norbert Kraut
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer discovery 11 (1) (2020)
Daniel Gerlach, Ulrike Tontsch-Grunt, Anke Baum, Johannes Popow, Dirk Scharn, Marco H Hofmann, Harald Engelhardt, Onur Kaya, Janina Beck, Norbert Schweifer, Thomas Gerstberger, Johannes Zuber, Fabio Savarese, Norbert Kraut
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene 37 (20) (2018)
Ulrich A Hirt, Irene C Waizenegger, Norbert Schweifer, Christian Haslinger, Daniel Gerlach, Jürgen Braunger, Ulrike Weyer-Czernilofsky, Heinz Stadtmüller, Ioannis Sapountzis, Gerd Bader, Andreas Zoephel, Bojan Bister, Anke Baum, Jens Quant, Norbert Kraut, Pilar Garin-Chesa, Günther R Adolf
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis 7 (2) (2018)
Barbara Krystyna Stepien, Cornelia Oppitz, Daniel Gerlach, Ugur Dag, Maria Novatchkova, Sebastian Krüttner, Alexander Stark, Krystyna Keleman
RNA-binding profiles of Drosophila CPEB proteins Orb and Orb2. Proceedings of the National Academy of Sciences of the United States of America 113 (45) (2016)

Daniel Gerlach.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Gerlach